3H
3HB.STU Hybrigenics Société Anonyme
- Market cap
- EUR 9.09M
- P/E
- -
- P/B
- 245.75x
- ROE
- -2,600.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 3HB.STU undervalued?
Graham numberThe Graham number of Hybrigenics Société Anonyme cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hybrigenics Société Anonyme fundamental analysis
No fundamental analysis for Hybrigenics Société Anonyme yet.
Hybrigenics Société Anonyme stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hybrigenics Société Anonyme
Hybrigenics SA, together with its subsidiaries, operates as a biotechnology company in France. The company engages in development of biotechnology in the field of biotechnology, oncology, regenerative medicine, and anti-aging medicine. It is also involved in the development of technical solutions using adipose tissue cells and stem cells. The company is headquartered in Gallargues-le-Montueux, France. Hybrigenics SA is a subsidiary of Diagnostic Medical Systems S.A.
Full company profileHybrigenics Société Anonyme financial statements
Hybrigenics Société Anonyme annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 3.61M | 1.88M | 76.7K | 235K | 151K | 147K | 1.57K | 612K | 614K | 661K |
| Gross Profit | 2.59M | -2.58M | 45.1K | 234K | -85.5K | -109K | -211K | 448K | 491K | 491K |
| Operating Income | -4.32M | -7.38M | -7.64M | -1.36M | -317K | -123K | -590K | -2.09M | -169K | -800K |
| EBITDA | - | -7.15M | -7.39M | -1.27M | -269K | 325K | -508K | -714K | -22.0K | -104K |
| Net Income | -5.26M | -7.96M | -7.53M | -736K | -327K | -69.2K | -564K | -7.87M | -1.10M | -962K |
| EPS | - | -0.17 | - | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 16.2M | 14.0M | 3.99M | 5.91M | 6.42M | 13.2M | 15.2M | 9.76M | 6.45M | 5.81M |
| Total Liabilities | 5.30M | 4.81M | 2.71M | 682K | 1.52M | 3.72M | 4.97M | 11.6M | 5.27M | 5.42M |
| Shareholders' Equity | 10.8M | 9.16M | 1.28M | 5.23M | 4.90M | 9.43M | 10.2M | -2.10M | 791K | 37.0K |
| Cash & Short-term Investments | 8.49M | 7.02M | 1.91M | 58.6K | - | 1.54M | 598K | 111K | 84.0K | 455K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.56M | -7.60M | - | - | - | - | - | -3.42M | 510K | 394K |
| Capital Expenditure | 203K | 136K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 153K | 482K | 252K |
| Free Cash Flow | - | -7.73M | - | - | - | - | - | -3.58M | 28.0K | 142K |
| Ratios | ||||||||||
| ROE | -48.7% | -86.9% | -587.3% | -14.1% | -6.7% | -0.7% | -5.5% | - | -139.2% | -2,600.0% |
| ROA | -32.5% | -56.9% | -188.5% | -12.4% | -5.1% | -0.5% | -3.7% | -80.6% | -17.1% | -16.6% |
| Net Profit Margin | -145.8% | -423.2% | -9,811.4% | -313.1% | -216.9% | -47.0% | -36,010.9% | -1,285.8% | -179.3% | -145.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hybrigenics Société Anonyme dividends
Hybrigenics Société Anonyme has not paid dividends in the last 10 fiscal years.
Who owns Hybrigenics Société Anonyme
- Insiders 34.82%
- Institutions 10.49%
- Public & others 54.69%
- Shares outstanding 1.11B
- Free float 326M
Hybrigenics Société Anonyme company profile
- Company name
- Hybrigenics Société Anonyme
- Ticker
- 3HB.STU
- ISIN
- FR0004153930
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 850 Boulevard Sébastien Brant, Strasbourg, France, 67400
- Phone
- 33 9 72 56 94 99
- Website
- aton-group.com
About Hybrigenics Société Anonyme
Hybrigenics SA, together with its subsidiaries, operates as a biotechnology company in France. The company engages in development of biotechnology in the field of biotechnology, oncology, regenerative medicine, and anti-aging medicine. It is also involved in the development of technical solutions using adipose tissue cells and stem cells. The company is headquartered in Gallargues-le-Montueux, France. Hybrigenics SA is a subsidiary of Diagnostic Medical Systems S.A.
Hybrigenics Société Anonyme management
2- Ms. Ayikoele AtayiGM & Chair of the Board of Directors
- Mr. Hadrien LanvinDeputy CEO & Director